Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Common Equity: 2020-2025

Historic Common Equity for Apellis Pharmaceuticals (APLS) over the last 6 years, with Sep 2025 value amounting to $401.2 million.

  • Apellis Pharmaceuticals' Common Equity rose 69.18% to $401.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $401.2 million, marking a year-over-year increase of 69.18%. This contributed to the annual value of $228.5 million for FY2024, which is 17.49% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Common Equity of $401.2 million as of Q3 2025, which was up 156.66% from $156.3 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Common Equity ranged from a high of $462.2 million in Q1 2022 and a low of -$334.4 million during Q2 2022.
  • Its 3-year average for Common Equity is $263.9 million, with a median of $237.1 million in 2024.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 160.97% in 2021, then soared by 794.80% in 2022.
  • Over the past 5 years, Apellis Pharmaceuticals' Common Equity (Quarterly) stood at $198.7 million in 2021, then fell by 14.49% to $169.9 million in 2022, then rose by 14.51% to $194.5 million in 2023, then climbed by 17.49% to $228.5 million in 2024, then soared by 69.18% to $401.2 million in 2025.
  • Its last three reported values are $401.2 million in Q3 2025, $156.3 million for Q2 2025, and $164.2 million during Q1 2025.